Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Analyst Ratings
Moderate Buy
13 Buy
5 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ACAD Stock 12 Month Forecast
Average Price Target
$29.61
▲(30.90% Upside)
| Highest Price Target$39.00 | Average Price Target$29.61 | Lowest Price Target$17.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$27
Hold
19.36%
Upside
Reiterated
10/22/25
Citi
$33
Buy
45.89%
Upside
Initiated
10/21/25
Morgan Stanley
$24
Hold
6.10%
Upside
Reiterated
10/19/25
ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product FocusWe think majority of investor focus will be on Daybue and whether growth in new patients can exceed the mid 30's. New patients, net of discontinuation stood at 987 unique U.S. patients in 2Q ( Exhibit 2 ), with management emphasizing the improved >50% 12-month persistence and >45% at 18 months. Of note, there was a net addition of 33 patients in 2Q25 (in line with 34 new patients in 1Q25), and we believe investor focus is likely to be on whether the growth in new patients, net of discontinuation, can exceed with mid-30s achieved in 1Q and 2Q. Daybue international expansion is underway via named-patient programs in Programs initiated in 2Q. Recall that EMA review is underway, with decision expected around 1Q26, and we believe commentary on EMA review progress and early ex-U.S. uptake should help to evaluate the commercial opportunity and timing.
RBC Capital
$40→$34
Buy
50.31%
Upside
Reiterated
10/08/25
Mizuho Securities
$22→$24
Hold
6.10%
Upside
Reiterated
10/08/25
Leerink Partners
$32→$30
Buy
32.63%
Upside
Reiterated
10/07/25
J.P. Morgan
$34→$33
Buy
45.89%
Upside
Reiterated
09/29/25
BMO Capital
$28→$26
Buy
14.94%
Upside
Reiterated
09/25/25
Deutsche Bank
$35→$29
Buy
28.21%
Upside
Reiterated
09/25/25
TD Cowen
$39→$35
Buy
54.73%
Upside
Reiterated
09/24/25
Robert W. Baird
$31
Buy
37.05%
Upside
Reiterated
09/24/25
Needham
$30→$28
Buy
23.78%
Upside
Reiterated
09/24/25
Stifel Nicolaus
―
Hold
―
Reiterated
09/24/25
Canaccord Genuity
$32
Buy
41.47%
Upside
Reiterated
09/24/25
Oppenheimer
$22→$21
Hold
-7.16%
Downside
Reiterated
09/24/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$27
Hold
19.36%
Upside
Reiterated
10/22/25
Citi
$33
Buy
45.89%
Upside
Initiated
10/21/25
Morgan Stanley
$24
Hold
6.10%
Upside
Reiterated
10/19/25
ACADIA Pharmaceuticals: Hold Rating Amid Pipeline Shifts and Product FocusWe think majority of investor focus will be on Daybue and whether growth in new patients can exceed the mid 30's. New patients, net of discontinuation stood at 987 unique U.S. patients in 2Q ( Exhibit 2 ), with management emphasizing the improved >50% 12-month persistence and >45% at 18 months. Of note, there was a net addition of 33 patients in 2Q25 (in line with 34 new patients in 1Q25), and we believe investor focus is likely to be on whether the growth in new patients, net of discontinuation, can exceed with mid-30s achieved in 1Q and 2Q. Daybue international expansion is underway via named-patient programs in Programs initiated in 2Q. Recall that EMA review is underway, with decision expected around 1Q26, and we believe commentary on EMA review progress and early ex-U.S. uptake should help to evaluate the commercial opportunity and timing.
RBC Capital
$40→$34
Buy
50.31%
Upside
Reiterated
10/08/25
Mizuho Securities
$22→$24
Hold
6.10%
Upside
Reiterated
10/08/25
Leerink Partners
$32→$30
Buy
32.63%
Upside
Reiterated
10/07/25
J.P. Morgan
$34→$33
Buy
45.89%
Upside
Reiterated
09/29/25
BMO Capital
$28→$26
Buy
14.94%
Upside
Reiterated
09/25/25
Deutsche Bank
$35→$29
Buy
28.21%
Upside
Reiterated
09/25/25
TD Cowen
$39→$35
Buy
54.73%
Upside
Reiterated
09/24/25
Robert W. Baird
$31
Buy
37.05%
Upside
Reiterated
09/24/25
Needham
$30→$28
Buy
23.78%
Upside
Reiterated
09/24/25
Stifel Nicolaus
―
Hold
―
Reiterated
09/24/25
Canaccord Genuity
$32
Buy
41.47%
Upside
Reiterated
09/24/25
Oppenheimer
$22→$21
Hold
-7.16%
Downside
Reiterated
09/24/25
Best Analysts Covering ACADIA Pharmaceuticals
1 Month
xxx
Success Rate
15/28 ratings generated profit
Average Return
+1.03%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.57% of your transactions generating a profit, with an average return of +1.03% per trade.
3 Months
xxx
Success Rate
15/28 ratings generated profit
Average Return
+1.96%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.57% of your transactions generating a profit, with an average return of +1.96% per trade.
1 Year
Success Rate
16/28 ratings generated profit
Average Return
+2.88%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +2.88% per trade.
2 Years
xxx
Success Rate
8/13 ratings generated profit
Average Return
+10.64%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +10.64% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ACAD Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
19
16
8
12
11
Buy
24
25
23
17
16
Hold
12
13
12
13
12
Sell
1
1
2
1
1
Strong Sell
0
0
0
0
0
total
56
55
45
43
40
Each month's total comprises the sum of three months' worth of ratings.
ACAD Financial Forecast
ACAD Stock Forecast FAQ
What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 29.61.
What is ACAD’s upside potential, based on the analysts’ average price target?
ACADIA Pharmaceuticals has 30.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACAD a Buy, Sell or Hold?
ACADIA Pharmaceuticals has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 1 sell ratings.
What is ACADIA Pharmaceuticals’s price target?
The average price target for ACADIA Pharmaceuticals is 29.61. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $39.00 ,the lowest forecast is $17.00. The average price target represents 30.90% Increase from the current price of $22.62.
The highest analyst price target is $39.00 ,the lowest forecast is $17.00. The average price target represents 30.90% Increase from the current price of $22.62.
What do analysts say about ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of ACAD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.